Streetbeat News

Products Services

ABBV

Health Canada has granted approval to AbbVie's QULIPTA for the prevention of chronic migraine in adults. This marks a significant milestone for AbbVie, expanding its portfolio in the migraine treatment market.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 12:05 pm

LPCN

Lipocine Inc. announced that its Phase 2 study data of LPCN 1148 will be presented at the EASL Congress 2024 in Milan, Italy. The study focuses on LPCN 1148's effectiveness in improving sarcopenia and hepatic encephalopathy in cirrhosis patients. LPCN 1148, containing testosterone laurate, aims to address unmet needs in cirrhosis management, including quality of life and reduction of decompensation events.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 12:04 pm

ATEC

Alphatec Holdings (NASDAQ:ATEC) has been analyzed by 7 analysts, showing a unanimous bullish outlook with a recent shift towards a higher average price target of $21.57, up 5.22% from the previous $20.50. The company, specializing in spinal surgery technology, has seen a notable revenue growth of 30.23% as of December 31, 2023, but struggles with profitability and high debt levels. Analysts from firms like Needham and Canaccord Genuity have adjusted their price targets and maintain a 'Buy' rating.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 12:01 pm

SXTP

60 Degrees Pharmaceuticals has announced the publication of a study titled 'Trial Planned to Evaluate Safety and Efficacy of Tafenoquine + Atovaquone/Azithromycin in Hospitalized Babesiosis Patients' in The Journal of Infectious Diseases. This publication marks a significant step in the research and development of treatments for Babesiosis, a disease caused by Babesia parasites. The study aims to assess the safety and efficacy of a combination treatment involving Tafenoquine and Atovaquone/Azithromycin in hospitalized patients suffering from this condition.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 12:00 pm

CYTK

Cytokinetics announced the topline results from its Phase 1 clinical study of CK-4021586, a new drug under development. The results could influence the company's future research directions and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:48 am

CARM

Carisma Therapeutics announced new preclinical data showing proof of concept for engineered anti-fibrotic macrophages in treating liver fibrosis, presented at the American Society of Gene and Cell Therapy Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:47 am

WIT

Wipro and Kognitos have announced a collaboration to deploy enterprise-ready GenAI-based business automation solutions. This partnership aims to enhance business processes through advanced AI technologies, potentially improving efficiency and innovation for clients.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:45 am

BRTX

BioRestorative Therapies has announced the development of a new exosome-based biologic program aimed at targeting obesity. This innovative approach represents a significant step forward in the company's efforts to address a major global health issue.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:41 am

OLMA

Olema Pharmaceuticals announced its plans to present new clinical data from its ongoing Phase 1b/2 study of Palazestrant in combination with CDK4/6 inhibitor Ribociclib at a conference in Berlin, Germany. This announcement could indicate significant progress in the company's research and development efforts, potentially impacting its stock performance.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:23 am

VERX

Vertex forecasts Q2 revenues to be between $159M-$162M, aligning with estimates of $160.348M, and maintains its full-year 2024 revenue projection of $650M-$660M, closely matching the $656.43M estimate. The company also anticipates a 28% growth in cloud revenue and an adjusted EBITDA of $130M-$135M for FY24.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 11:18 am